Separating right ventricular function from pulmonary arterial hypertension in systemic sclerosis

Circulation

Volumn 133, Issue 24, 2016, Pages 2345-2347

  Maron, Bradley A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOPULMONARY HEMODYNAMICS; EDITORIAL; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PERFORMANCE; HEART RIGHT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE VOLUME; HEART VENTRICLE CONTRACTILITY; HUMAN; LUNG MECHANICS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; SYSTEMIC SCLEROSIS;

FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; HYPERTENSION, PULMONARY; SCLERODERMA, SYSTEMIC; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84967223139     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023237     Document Type: Editorial

References (20)

1. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am. 1996; 22: 841-860
2. Hinchcliff M, Fischer A, Schiopu E, Steen VD; PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011; 38: 2172-2179. doi: 10.3899/jrheum.101243
3. de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol. 2009; 184: 83-99. doi: 10.1083/jcb.200806049
4. Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension, part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation. 2015; 131: 2079-2091. doi: 10.1161/CIRCULATIONAHA.114.006980
5. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurty MS, Weir EK, Archer SL. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation.2006; 113: 2630-2641
6. Alastalo TP, Li M, Perez VdJ, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, Rabinovitch M. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011; 121: 3735-3746. doi: 10.1172/JCI43382
7. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, Hatron PY, Humbert M, Launay D. Survival and prognostic factors in systemic sclerosis-Associated pulmonary hypertension: a systematic review and meta-Analysis. Arthritis Rheum. 2013; 65: 2412-2423. doi: 10.1002/art.38029
8. McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015; 46: 405-413. doi: 10.1183/13993003.02044-2014
9. Hsu S, Houston BA, Tampakakis E, Bacher AC, Rhodes PS, Mathai SC, Damico RL, Kolb TM, Hummers LK, Shah AA, McMahan Z, Corona-Villalobos CP, Zimmerman SL, Wigley FM, Hassoun PM, Kass DA, Tedford RJ. Right ventricular functional reserve in pulmonary arterial hypertension. Circulation. 2016; 133: 2413-2422. DOI: 10.1161/CIRCULATIONAHA.116.022082
10. Tedford RJ, Mudd JO, Girgis RE, Mathai SC, Zaiman AL, Housten-Harris T, Boyce D, Kelemen BW, Bacher AC, Shah AA, Hummers LK, Wigley FM, Russell SD, Saggar R, Saggar R, Maughan WL, Hassoun PM, Kass DA. Right ventricular dysfunction in systemic sclerosis-Associated pulmonary arterial hypertension. Circ Heart Fail. 2013; 6: 953-963. doi: 10.1161/CIRCHEARTFAILURE.112.000008
11. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Tröster N, Hesse C, Salmhofer W, Graninger W, Gruenig E, Rubin LJ, Olschewski H. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med. 2009; 180: 881-886. doi: 10.1164/rccm.200904-0563OC
12. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC. Ambrisentan and tadalafil up-front combination therapy in scleroderma-Associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015; 192: 1102-1110. doi: 10.1164/rccm.201507-1398OC
13. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016; 133: 1240-1248. doi: 10.1161/CIRCULATIONAHA.115.020207
14. Austin ED, Kawut SM, Gladwin MT, Abman SH. Pulmonary hypertension: NHLBI Workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc. 2014; 11: S178-185
15. Harrison A, Hatton N, Ryan JJ. The right ventricle under pressure: evaluating the adaptive and maladaptive changes in the right ventricle in pulmonary arterial hypertension using echocardiography (2013 Grover Conference series). Pulm Circ. 2015; 5: 29-47
16. Rain S, Bos Dda S, Handoko ML, Westerhof N, Stienen G, Ottenheijm C, Goebel M, Dorfmüller P, Guignabert C, Humbert M, Bogaard HJ, Remedios CD, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS. Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertension. J Am Heart Assoc. 2014; 3: e000716. doi: 10.1161/JAHA.113.000716
17. Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish KM, Kohlbrenner E, Hammoudi N, Kho C, Lee A, Ibáñez B, García-Alvarez A, Zsebo K, Maron BA, Plataki M, Fuster V, Leopold JA, Hajjar RJ. Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model. J Am Coll Cardiol. 2016; 67: 2032-2046. doi: 10.1016/j.jacc.2016.02.049
18. Torbicki A. Hypertension: definition of pulmonary hypertension challenged? Nat Rev Cardiol. 2016; 13: 250-251. doi: 10.1038/nrcardio.2016.44
19. Kovacs G, Olschewski H. Borderline pulmonary pressures in scleroderma: a pre-pulmonary arterial hypertension condition? Arthritis Res Ther. 2015; 17: 123. doi: 10.1186/s13075-015-0649-7
20. Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther. 2014; 16: 493. doi: 10.1186/s13075-014-0493-1